ArticleACS omega2026
Glucuronidated Hydroxyphenylacetic and Hydroxyphenylpropanoic Acids as Standards for Bioavailability Studies with Flavonoids.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucuronidation is a major phase II biotransformation of (poly)-phenols leading to potentially bioactive metabolites. Due to the limited availability of authentic standards, in this work, we have focused on the glucuronidation of a series of mono- and dihydroxyphenolic acids. Their reactivity with two glucuronidation reagents, 2,3,4-triaceto-1-bromo-α-d-glucuronic acid methyl ester and Schmidt imidate, was investigated. The use of Schmidt imidate led to the successful synthesis of six target glucuronides in moderate to excellent yields. Subsequent deprotection of these compounds afforded the final glucuronides of 2-hydroxyphenylacetic, 3-hydroxyphenylacetic, 4-hydroxyphenylacetic, 3,4-dihydroxyphenylacetic, 3-(4-hydroxyphenyl)-propionic, and 3-(3,4-dihydroxyphenyl)-propionic acid. These compounds, which are plausible polyphenolic metabolites, were fully characterized and used in a pilot metabolic study in rats after administration of a hawthorn berry extract (475 mg/kg). UHPLC-HRMS analysis identified two of the glucuronides, namely 4-hydroxyphenylacetic acid glucuronide and 3-hydroxyphenylacetic acid glucuronide in rat plasma, confirming their
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.